Measurement of Proteasome Activity in Peripheral Blood Mononuclear Cells as an Indicator of Susceptibility to Bortezomib-Induced Severe Neurological Adverse Events in Patients with Multiple Myeloma.

@article{Cho2015MeasurementOP,
  title={Measurement of Proteasome Activity in Peripheral Blood Mononuclear Cells as an Indicator of Susceptibility to Bortezomib-Induced Severe Neurological Adverse Events in Patients with Multiple Myeloma.},
  author={Yukiko Cho and Mitsuo Hori and Yasushi Okoshi and Fumie Fujisawa and Atsushi Shinagawa and Daisuke Kudo and Takuya Komeno and Chikashi Yoshida and Yukitaka Katsura and Ikuyo Ota and Seiichi Shimizu and Masaharu Kamoshita and Katsuhiro Sasaki and Keiji Tanaka and Harumi Yamamoto Mukai and Hiroshi Kojima},
  journal={Acta haematologica},
  year={2015},
  volume={134 1},
  pages={25-31}
}
AIMS To explore the biomarker for predicting the occurrence of adverse events in myeloma patients treated by intravenous bortezomib, we measured proteasome activity in peripheral blood mononuclear cells. METHODS Samples were obtained from 34 bortezomib-naïve patients. Proteasome activity was measured at pre- and postchemotherapy phase by using a synthetic substrate. RESULTS Bortezomib injection resulted in a dramatic decrease in proteasome activity, reaching 32.4 ± 18.79% (mean ± SD) of the… CONTINUE READING